{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T18:32:19Z","timestamp":1791484339313,"version":"4.3.4"},"reference-count":83,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatric Clinics of North America"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.psc.2024.08.008","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T12:41:00Z","timestamp":1733316060000},"page":"91-107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Pharmacotherapy for Tourette Syndrome"],"prefix":"10.1016","volume":"48","author":[{"given":"Brittney O.","family":"Jurgen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4127-7941","authenticated-orcid":false,"given":"Erica L.","family":"Greenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.psc.2024.08.008_bib1","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.neubiorev.2021.08.001","article-title":"The female Tourette patient: sex differences in Tourette disorder","volume":"129","author":"Garris","year":"2021","journal-title":"Neurosci Biobehav Rev"},{"issue":"5","key":"10.1016\/j.psc.2024.08.008_bib2","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.comppsych.2011.07.004","article-title":"A\u00a0phenomenological investigation of women with Tourette or other chronic tic disorders","volume":"53","author":"Lewin","year":"2012","journal-title":"Compr Psychiatr"},{"issue":"3","key":"10.1016\/j.psc.2024.08.008_bib3","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/dmcn.13285","article-title":"Preliminary evaluation of child self-rating using the child Tourette syndrome impairment scale","volume":"59","author":"Cloes","year":"2016","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.psc.2024.08.008_bib4","article-title":"Differences in tic severity among adolescent girls and boys with tourette syndrome during the pandemic","author":"Larsh","year":"2023","journal-title":"Neuropediatrics"},{"issue":"Pt 2","key":"10.1016\/j.psc.2024.08.008_bib5","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1093\/brain\/awu311","article-title":"Altered structural connectivity of cortico-striato-pallido-thalamic networks in Gilles de la Tourette syndrome","volume":"138","author":"Worbe","year":"2015","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.psc.2024.08.008_bib6","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1021\/acschemneuro.7b00460","article-title":"Update on the pharmacological treatment of tics with dopamine-modulating agents","volume":"9","author":"Mogwitz","year":"2018","journal-title":"ACS Chem Neurosci"},{"issue":"3","key":"10.1016\/j.psc.2024.08.008_bib7","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00787-021-01899-z","article-title":"European clinical guidelines for Tourette syndrome and other tic disorders\u2014version 2.0. Part III: pharmacological treatment","volume":"31","author":"Roessner","year":"2021","journal-title":"Eur Child Adolesc Psychiatr"},{"issue":"19","key":"10.1016\/j.psc.2024.08.008_bib8","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1212\/WNL.0000000000007466","article-title":"Practice guideline recommendations summary: treatment of tics in people with Tourette syndrome and chronic tic disorders","volume":"92","author":"Pringsheim","year":"2019","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.psc.2024.08.008_bib9","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1001\/archpsyc.1983.01790100081011","article-title":"Treatment of Gilles de la Tourette\u2019s syndrome with clonidine and neuroleptics","volume":"40","author":"Shapiro","year":"1983","journal-title":"Arch Gen Psychiatr"},{"issue":"6","key":"10.1016\/j.psc.2024.08.008_bib10","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.neubiorev.2012.09.008","article-title":"Systematic review: pharmacological treatment of tic disorders \u2013 efficacy of antipsychotic and alpha-2 adrenergic agonist agents","volume":"37","author":"Weisman","year":"2013","journal-title":"Neurosci Biobehav Rev"},{"issue":"2","key":"10.1016\/j.psc.2024.08.008_bib11","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S2352-4642(22)00316-9","article-title":"Comparative efficacy, tolerability, and acceptability of pharmacological interventions for the treatment of children, adolescents, and young adults with Tourette\u2019s syndrome: a systematic review and network meta-analysis","volume":"7","author":"Farhat","year":"2023","journal-title":"The Lancet Child & Adolescent Health"},{"issue":"8","key":"10.1016\/j.psc.2024.08.008_bib12","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/archpsyc.1989.01810080052006","article-title":"Controlled study of haloperidol, pimozide, and placebo for the treatment of Gilles de la Tourette\u2019s syndrome","volume":"46","author":"Shapiro","year":"1989","journal-title":"Arch Gen Psychiatr"},{"issue":"8","key":"10.1016\/j.psc.2024.08.008_bib13","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1176\/ajp.154.8.1057","article-title":"Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette\u2019s disorder","volume":"154","author":"Sallee","year":"1997","journal-title":"Am J Psychiatr"},{"issue":"1","key":"10.1016\/j.psc.2024.08.008_bib14","doi-asserted-by":"crossref","first-page":"50","DOI":"10.4088\/JCP.v62n0111","article-title":"Risperidone versus pimozide in Tourette\u2019s disorder","volume":"62","author":"Bruggeman","year":"2001","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"2","key":"10.1016\/j.psc.2024.08.008_bib15","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0361-9230(83)90192-2","article-title":"Treatment approaches in Gilles de la Tourette syndrome","volume":"11","author":"Borison","year":"1983","journal-title":"Brain Res Bull"},{"issue":"3","key":"10.1016\/j.psc.2024.08.008_bib16","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1001\/archneur.1984.04050150049015","article-title":"Fluphenazine and multifocal tic disorders","volume":"41","author":"Goetz","year":"1984","journal-title":"Arch Neurol"},{"issue":"1","key":"10.1016\/j.psc.2024.08.008_bib17","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/mds.25692","article-title":"Long-term efficacy and safety of fluphenazine in patients with Tourette syndrome","volume":"29","author":"Wijemanne","year":"2013","journal-title":"Mov Disord"},{"issue":"5","key":"10.1016\/j.psc.2024.08.008_bib18","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1080\/14656566.2020.1721465","article-title":"Current pharmacotherapy for tic disorder","volume":"21","author":"Cothros","year":"2020","journal-title":"Expet Opin Pharmacother"},{"issue":"4","key":"10.1016\/j.psc.2024.08.008_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta20040","article-title":"Clinical effectiveness and patient perspectives of different treatment strategies for tics in children and adolescents with Tourette syndrome: a systematic review and qualitative analysis","volume":"20","author":"Hollis","year":"2016","journal-title":"Health Technol Assess"},{"issue":"9","key":"10.1016\/j.psc.2024.08.008_bib20","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1089\/cap.2016.0026","article-title":"Randomized, double-blind, placebo-controlled trial demonstrates the efficacy and safety of oral aripiprazole for the treatment of tourette\u2019s disorder in children and adolescents","volume":"27","author":"Sallee","year":"2017","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"issue":"5","key":"10.1016\/j.psc.2024.08.008_bib21","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/JCP.0000000000000760","article-title":"Feasibility and relevance of antipsychotic safety monitoring in children with tourette syndrome","volume":"37","author":"Pringsheim","year":"2017","journal-title":"J\u00a0Clin Psychopharmacol"},{"issue":"7","key":"10.1016\/j.psc.2024.08.008_bib22","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1212\/01.WNL.0000055434.39968.67","article-title":"A\u00a0placebo-controlled trial of risperidone in Tourette syndrome","volume":"60","author":"Scahill","year":"2003","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.psc.2024.08.008_bib23","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/00004714-200202000-00006","article-title":"Risperidone in the treatment of Tourette syndrome: a double-blind, placebo-controlled trial","volume":"22","author":"Dion","year":"2002","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.psc.2024.08.008_bib24","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/B978-0-12-411546-0.00010-X","article-title":"Clinical pharmacology of dopamine-modulating agents in Tourette\u2019s syndrome","volume":"112","author":"Mogwitz","year":"2013","journal-title":"Int Rev Neurobiol"},{"issue":"6","key":"10.1016\/j.psc.2024.08.008_bib25","first-page":"443","article-title":"Olanzapine in severe Gilles de la Tourette syndrome: a 52-week double-blind cross-over study vs. low-dose pimozide","volume":"247","author":"Onofrj","year":"2000","journal-title":"J\u00a0Neurol"},{"issue":"4","key":"10.1016\/j.psc.2024.08.008_bib26","first-page":"66","article-title":"Olanzapine for treatment of Tourette syndrome: a double-blind randomized controlled trial","volume":"9","author":"Ji","year":"2005","journal-title":"Chin J Clin Rehabil"},{"issue":"4","key":"10.1016\/j.psc.2024.08.008_bib27","doi-asserted-by":"crossref","first-page":"290","DOI":"10.4088\/JCP.v62n0412","article-title":"An open-label study of the treatment efficacy of olanzapine for Tourette\u2019s disorder","volume":"62","author":"Budman","year":"2001","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"5","key":"10.1016\/j.psc.2024.08.008_bib28","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1089\/cap.2007.135","article-title":"Effectiveness and tolerability of open label olanzapine in children and adolescents with tourette syndrome","volume":"18","author":"McCracken","year":"2008","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"issue":"1","key":"10.1016\/j.psc.2024.08.008_bib29","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/00004850-200015010-00003","article-title":"Effective open-label treatment of Tourette\u02bcs disorder with olanzapine","volume":"15","author":"Stamenkovic","year":"2000","journal-title":"Int Clin Psychopharmacol"},{"issue":"3","key":"10.1016\/j.psc.2024.08.008_bib30","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1089\/104454603322572624","article-title":"Quetiapine treatment of children and adolescents with Tourette\u2019s disorder","volume":"13","author":"Mukaddes","year":"2003","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"issue":"3","key":"10.1016\/j.psc.2024.08.008_bib31","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/00004583-200003000-00010","article-title":"Ziprasidone treatment of children and adolescents with Tourette\u2019s syndrome: a pilot study","volume":"39","author":"Sallee","year":"2000","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatr"},{"issue":"8","key":"10.1016\/j.psc.2024.08.008_bib32","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/01.CHI.0000046897.27264.46","article-title":"Pharmacodynamics of ziprasidone in children and adolescents: impact on dopamine transmission","volume":"42","author":"Sallee","year":"2003","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatr"},{"issue":"12","key":"10.1016\/j.psc.2024.08.008_bib33","first-page":"1068","article-title":"Exacerbation of tics secondary to clozapine therapy","volume":"42","author":"Bastiampillai","year":"2008","journal-title":"Aust N Z J Psychiatr"},{"issue":"3","key":"10.1016\/j.psc.2024.08.008_bib34","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/00004583-200203000-00013","article-title":"Risperidone versus clonidine in the treatment of children and adolescents with Tourette\u2019s syndrome","volume":"41","author":"Gaffney","year":"2002","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatr"},{"issue":"4","key":"10.1016\/j.psc.2024.08.008_bib35","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/archpsyc.1991.01810280040006","article-title":"Clonidine treatment of Gilles de la Tourette\u2019s syndrome","volume":"48","author":"Leckman","year":"1991","journal-title":"Arch Gen Psychiatr"},{"issue":"7","key":"10.1016\/j.psc.2024.08.008_bib36","first-page":"537","article-title":"Zhongguo dang dai er ke za zhi","volume":"11","author":"Kang","year":"2009","journal-title":"Chin J Contemp Pediatr"},{"issue":"9","key":"10.1016\/j.psc.2024.08.008_bib37","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1080\/00048670802277222","article-title":"Randomized double-blind multicentre placebo-controlled clinical trial of the clonidine adhesive patch for the treatment of tic disorders","volume":"42","author":"Du","year":"2008","journal-title":"Aust N Z J Psychiatr"},{"issue":"7","key":"10.1016\/j.psc.2024.08.008_bib38","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1176\/appi.ajp.158.7.1067","article-title":"A\u00a0placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder","volume":"158","author":"Scahill","year":"2001","journal-title":"Am J Psychiatr"},{"issue":"6","key":"10.1016\/j.psc.2024.08.008_bib39","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/00002826-200211000-00009","article-title":"Neuropsychiatric effects of guanfacine in children with mild tourette syndrome: a pilot study","volume":"25","author":"Cummings","year":"2002","journal-title":"Clin Neuropharmacol"},{"issue":"9","key":"10.1016\/j.psc.2024.08.008_bib40","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1089\/cap.2017.0024","article-title":"Extended-release guanfacine does not show a large effect on tic severity in children with chronic Tic disorders","volume":"27","author":"Murphy","year":"2017","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"issue":"6","key":"10.1016\/j.psc.2024.08.008_bib41","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1093\/brain\/aws104","article-title":"Widespread abnormality of the \u03b3-aminobutyric acid-ergic system in Tourette syndrome","volume":"135","author":"Lerner","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.psc.2024.08.008_bib42","first-page":"245","article-title":"Clonidine and clonazepam in Tourette syndrome","volume":"58","author":"Goet","year":"1992","journal-title":"Adv Neurol"},{"issue":"6","key":"10.1016\/j.psc.2024.08.008_bib43","first-page":"296","article-title":"Therapeutical effects of clonidine and clonazepam in children with tick syndrome","volume":"35","author":"Drt\u00edlkov\u00e1","year":"1994","journal-title":"Homeost Health & Dis"},{"issue":"1","key":"10.1016\/j.psc.2024.08.008_bib44","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1136\/jnnp.2009.185348","article-title":"A\u00a0randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome","volume":"81","author":"Jankovic","year":"2009","journal-title":"J\u00a0Neurol Neurosurg Psychiatr"},{"issue":"5","key":"10.1016\/j.psc.2024.08.008_bib45","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1089\/cap.2019.0161","article-title":"Revisiting the efficacy and tolerability of topiramate for tic disorders: a meta-analysis","volume":"30","author":"Yu","year":"2020","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"issue":"5","key":"10.1016\/j.psc.2024.08.008_bib46","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1177\/088307389901400508","article-title":"Tics in tourette syndrome: new treatment options","volume":"14","author":"Awaad","year":"1999","journal-title":"J\u00a0Child Neurol"},{"issue":"5","key":"10.1016\/j.psc.2024.08.008_bib47","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1212\/WNL.56.5.599","article-title":"Baclofen treatment in Tourette syndrome: a double-blind, placebo-controlled, crossover trial","volume":"56","author":"Singer","year":"2001","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.psc.2024.08.008_bib48","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/jcpp.12432","article-title":"A\u00a0proprietary herbal medicine (5-Ling Granule) for Tourette syndrome: a randomized controlled trial","volume":"57","author":"Zheng","year":"2015","journal-title":"JCPP (J Child Psychol Psychiatry)"},{"issue":"4","key":"10.1016\/j.psc.2024.08.008_bib49","doi-asserted-by":"crossref","first-page":"212","DOI":"10.5582\/bst.2012.v6.4.212","article-title":"Effects of Chinese herbal medicine Ningdong Granule on regulating dopamine (DA)\/serotonin (5-TH) and gamma-amino butyric acid (GABA) in patients with Tourette syndrome","volume":"6","author":"Wang","year":"2012","journal-title":"BioScience Trends"},{"issue":"6","key":"10.1016\/j.psc.2024.08.008_bib50","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/j.1600-0447.1998.tb10127.x","article-title":"Cannabinoids: possible role in patho-physiology and therapy of Gilles de la Tourette syndrome","volume":"98","author":"M\u00fcller-Vahl","year":"1998","journal-title":"Acta Psychiatr Scand"},{"issue":"4","key":"10.1016\/j.psc.2024.08.008_bib51","doi-asserted-by":"crossref","first-page":"459","DOI":"10.4088\/JCP.v64n0417","article-title":"Delta 9-Tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome","volume":"64","author":"Muller-Vahl","year":"2003","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.psc.2024.08.008_bib52","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300012","article-title":"Tetrahydrocannabinol and cannabidiol in Tourette syndrome","author":"Mosley","year":"2023","journal-title":"NEJM evidence"},{"key":"10.1016\/j.psc.2024.08.008_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2023.115135","article-title":"CANNA-TICS: efficacy and safety of oral treatment with nabiximols in adults with chronic tic disorders - results of a prospective, multicenter, randomized, double-blind, placebo controlled, phase IIIb superiority study","volume":"323","author":"M\u00fcller-Vahl","year":"2023","journal-title":"Psychiatr Res"},{"issue":"1","key":"10.1016\/j.psc.2024.08.008_bib54","doi-asserted-by":"crossref","first-page":"28","DOI":"10.5603\/PJNNS.a2021.0081","article-title":"Cannabis-based medicine in treatment of patients with Gilles de la Tourette syndrome","volume":"56","author":"Szejko","year":"2021","journal-title":"Neurol Neurochir Pol"},{"key":"10.1016\/j.psc.2024.08.008_bib55","doi-asserted-by":"crossref","first-page":"422","DOI":"10.5334\/tohm.287","article-title":"Deutetrabenazine in tics associated with tourette syndrome","volume":"6","author":"Jankovic","year":"2016","journal-title":"Tremor and Other Hyperkinetic Movements"},{"issue":"4","key":"10.1016\/j.psc.2024.08.008_bib56","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/14737175.2021.1898948","article-title":"Clinical development of valbenazine for tics associated with Tourette syndrome","volume":"21","author":"Farber","year":"2021","journal-title":"Expert Rev Neurother"},{"issue":"9","key":"10.1016\/j.psc.2024.08.008_bib57","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1002\/mdc3.13849","article-title":"Safety and efficacy of long-term deutetrabenazine use in children and adolescents with tics associated with tourette syndrome: an open-label extension study","volume":"10","author":"Jankovic","year":"2023","journal-title":"Movement Disorders Clinical Practice"},{"issue":"8","key":"10.1016\/j.psc.2024.08.008_bib58","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1002\/mds.27457","article-title":"Ecopipam, a D1 receptor antagonist, for treatment of tourette syndrome in children: a randomized, placebo-controlled crossover study","volume":"33","author":"Gilbert","year":"2018","journal-title":"Mov Disord"},{"issue":"2","key":"10.1016\/j.psc.2024.08.008_bib59","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2022-059574","article-title":"Ecopipam for Tourette syndrome: a randomized trial","volume":"151","author":"Gilbert","year":"2023","journal-title":"Pediatrics"},{"issue":"48","key":"10.1016\/j.psc.2024.08.008_bib60","article-title":"Tourette syndrome and other tic disorders in childhood, adolescence and adulthood","volume":"109","author":"Ludolph","year":"2012","journal-title":"Deutsches Aerzteblatt Online"},{"issue":"12","key":"10.1016\/j.psc.2024.08.008_bib61","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1177\/0883073808331363","article-title":"The presence of comorbidity in tourette syndrome increases the need for pharmacological treatment","volume":"24","author":"Debes","year":"2009","journal-title":"J\u00a0Child Neurol"},{"issue":"1","key":"10.1016\/j.psc.2024.08.008_bib62","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/00004583-200301000-00016","article-title":"Disruptive behavior in children with Tourette\u2019s syndrome: association with ADHD comorbidity, tic severity, and functional impairment","volume":"42","author":"Sukhodolsky","year":"2003","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatr"},{"issue":"9","key":"10.1016\/j.psc.2024.08.008_bib63","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.jaac.2015.06.011","article-title":"Meta-analysis: risk of tics associated with psychostimulant use in randomized, placebo-controlled trials","volume":"54","author":"Cohen","year":"2015","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatr"},{"issue":"6","key":"10.1016\/j.psc.2024.08.008_bib64","article-title":"Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders","volume":"6","author":"Osland","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.psc.2024.08.008_bib65","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1212\/WNL.58.4.527","article-title":"Treatment of ADHD in children with tics: a randomized controlled trial","volume":"58","year":"2002","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.psc.2024.08.008_bib66","article-title":"Pharmacological treatment for Attention Deficit Hyperactivity Disorder (ADHD) in children with comorbid tic disorders","author":"Pringsheim","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.psc.2024.08.008_bib67","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/B978-0-12-411546-0.00014-7","article-title":"Clinical pharmacology of comorbid attention deficit hyperactivity disorder in tourette syndrome","volume":"112","author":"Rizzo","year":"2013","journal-title":"Int Rev Neurobiol"},{"issue":"1","key":"10.1016\/j.psc.2024.08.008_bib68","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/dmcn.14707","article-title":"What is the effect of pharmacological treatment for attention-deficit\/hyperactivity disorder in children with comorbid tic disorders? A Cochrane Review summary with commentary","volume":"63","author":"Malmivaara","year":"2020","journal-title":"Dev Med Child Neurol"},{"issue":"4","key":"10.1016\/j.psc.2024.08.008_bib69","first-page":"357","article-title":"Reflections on the meaning and structure of the horizontal\/vertical distinction","volume":"16","author":"Shavitt","year":"2006","journal-title":"J\u00a0Consum Psychol"},{"issue":"2","key":"10.1016\/j.psc.2024.08.008_bib70","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1017\/S0033291717001672","article-title":"Genetic and phenotypic overlap of specific obsessive-compulsive and attention-deficit\/hyperactive subtypes with Tourette syndrome","volume":"48","author":"Hirschtritt","year":"2017","journal-title":"Psychol Med"},{"issue":"1","key":"10.1016\/j.psc.2024.08.008_bib71","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.psychres.2008.06.008","article-title":"Tourette\u2019s syndrome, trichotillomania, and obsessive\u2013compulsive disorder: how closely are they related?","volume":"170","author":"Ferr\u00e3o","year":"2009","journal-title":"Psychiatr Res"},{"issue":"5","key":"10.1016\/j.psc.2024.08.008_bib72","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/00004714-199310000-00008","article-title":"The efficacy of fluvoxamine in obsessive-compulsive disorder: effects of comorbid chronic tic disorder","volume":"13","author":"McDougle","year":"1993","journal-title":"J\u00a0Clin Psychopharmacol"},{"issue":"3","key":"10.1016\/j.psc.2024.08.008_bib73","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.biopsych.2006.09.035","article-title":"Tics moderate treatment outcome with sertraline but not cognitive-behavior therapy in pediatric obsessive-compulsive disorder","volume":"61","author":"March","year":"2007","journal-title":"Biol Psychiatr"},{"issue":"7","key":"10.1016\/j.psc.2024.08.008_bib75","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/sj.mp.4001823","article-title":"A\u00a0systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder","volume":"11","author":"Bloch","year":"2006","journal-title":"Mol Psychiatr"},{"issue":"8","key":"10.1016\/j.psc.2024.08.008_bib74","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2174\/1570159X16666180828095131","article-title":"Psychopharmacotherapy of obsessive-compulsive symptoms within the framework of Tourette syndrome","volume":"17","author":"Rothenberger","year":"2019","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.psc.2024.08.008_bib76","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/B978-0-12-411546-0.00013-5","article-title":"Clinical pharmacology of comorbid obsessive\u2013compulsive disorder in Tourette syndrome","volume":"112","author":"Neri","year":"2013","journal-title":"Int Rev Neurobiol"},{"issue":"9","key":"10.1016\/j.psc.2024.08.008_bib77","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1177\/02698811211032445","article-title":"Pharmacological treatment for Tourette syndrome in children and adults: what is the quality of the evidence? A systematic review","volume":"35","author":"Besag","year":"2021","journal-title":"J\u00a0Psychopharmacol"},{"issue":"1","key":"10.1016\/j.psc.2024.08.008_bib78","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0022-3999(02)00584-6","article-title":"Clinical phenomenology of episodic rage in children with Tourette syndrome","volume":"55","author":"Budman","year":"2003","journal-title":"J\u00a0Psychosom Res"},{"issue":"1\u20132","key":"10.1016\/j.psc.2024.08.008_bib79","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jns.2011.06.032","article-title":"The role of impulse control disorders in Tourette syndrome: an exploratory study","volume":"310","author":"Frank","year":"2011","journal-title":"J\u00a0Neurol Sci"},{"issue":"5","key":"10.1016\/j.psc.2024.08.008_bib80","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1136\/adc.81.5.440","article-title":"Parent perceptions of symptom severity in Tourette\u2019s syndrome","volume":"81","author":"Dooley","year":"1999","journal-title":"Arch Dis Child"},{"issue":"9","key":"10.1016\/j.psc.2024.08.008_bib81","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1177\/0883073808315412","article-title":"Methylphenidate in children with oppositional defiant disorder and both comorbid chronic multiple tic disorder and ADHD","volume":"23","author":"Gadow","year":"2008","journal-title":"J\u00a0Child Neurol"},{"issue":"5","key":"10.1016\/j.psc.2024.08.008_bib82","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1089\/cap.2007.061","article-title":"Aripiprazole in children and adolescents with Tourette disorder with and without explosive outbursts","volume":"18","author":"Budman","year":"2008","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"issue":"1","key":"10.1016\/j.psc.2024.08.008_bib83","first-page":"45","article-title":"Guanfacine for the treatment of cognitive disorders: a century of discoveries at Yale","volume":"85","author":"Arnsten","year":"2012","journal-title":"Yale J Biol Med"}],"container-title":["Psychiatric Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0193953X24000789?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0193953X24000789?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T17:03:18Z","timestamp":1749488598000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0193953X24000789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":83,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0193953X24000789"],"URL":"https:\/\/doi.org\/10.1016\/j.psc.2024.08.008","relation":{},"ISSN":["0193-953X"],"issn-type":[{"value":"0193-953X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacotherapy for Tourette Syndrome","name":"articletitle","label":"Article Title"},{"value":"Psychiatric Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psc.2024.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}